Folivis · Learn
Source notes that explain the scope and limits of research cited across Folivis guides.
Roberts et al. (2014), PMID 24773771. Discusses sulfotransferase-associated response; it does not establish universal minoxidil resistance.
Clinical research · Applies to response variability in women with androgenetic alopecia.
Open PubMedChecked October 20, 2026 · Related Folivis guide:reviewing a minoxidil result
Olsen et al. (1990), PMID 2180995. In 31 men, gains peaked near one year and gradually declined over 4.5–5 years while remaining above baseline.
Clinical study · A small study; its findings do not promise an individual outcome.
Open PubMedChecked October 20, 2026 · Related Folivis guide:reviewing a minoxidil result
2019 review of response, formulation, activation and adherence factors in topical minoxidil use.
Review · Context for treatment variability; not a Folivis product trial.
Open reviewChecked October 20, 2026 · Related Folivis guide:reviewing a minoxidil result
Official June 2026 prescribing information reports hair loss in 3.3% versus 1% in specified injection studies 2, 3 and 4 at 2.4 mg.
Official product label · Applies to these Wegovy study groups, not all GLP-1 medicines.
Open prescribing informationChecked October 20, 2026 · Related Folivis guide:GLP-1 treatment and hair shedding
Pooled studies 1 and 2 report hair loss of 5%, 4% and 5% at 5, 10 and 15 mg, versus 1% with placebo.
Official product label · Applies to studied Zepbound doses and populations.
Open prescribing informationChecked October 20, 2026 · Related Folivis guide:GLP-1 treatment and hair shedding
Four-organization 2025 advisory highlights nutrition assessment, gastrointestinal symptom management, nutrient-dense meals, protein and micronutrient adequacy.
Professional nutrition advisory · Does not establish NOURISH efficacy for GLP-1-related hair changes.
Open PubMedChecked October 20, 2026 · Related Folivis guide:GLP-1 treatment and hair shedding
Chaikittisilpa et al. (2022) report a clinic-based cross-sectional study. It should not be read as a population-wide rate for all postmenopausal women.
Clinic-based observational research · Population and setting limit generalization.
Open PubMedChecked October 20, 2026 · Related Folivis guide:menopause and hair thinning
The American Academy of Dermatology describes signs such as a widening part and explains the role of pattern history and diagnosis.
Dermatology education · Helpful for recognizing patterns, not self-diagnosis.
Open AAD guideChecked October 20, 2026 · Related Folivis guide:menopause and hair thinning
The British Association of Dermatologists notes that illness, weight change and dietary restriction can precede diffuse shedding, often noticed around three months after a trigger.
Professional patient guidance · Timing can guide discussion but does not diagnose cause.
Open BAD guideChecked October 20, 2026 · Related Folivis guide:menopause and hair thinning
AAD guidance emphasizes cleansing the scalp, conditioning lengths and gentle handling.
Dermatology care guidance · Supports routine care, not a hair-growth treatment claim.
Open AAD guideChecked October 20, 2026 · Related Folivis guide:applying a scalp serum
Folivis product directions: apply once daily to a clean, dry or towel-dried scalp and leave in. The bottle contains 60 mL; no per-use mL dose is specified.
Folivis product fact · Product directions, not independent clinical evidence.
Review product factsChecked October 20, 2026 · Related Folivis guide:applying a scalp serum
Drake et al. (2023), a systematic review of 30 studies, found possible benefits for selected supplements, dependent on formula and study design.
Systematic review · Does not establish a universal benefit or NOURISH efficacy.
Open PubMedChecked October 20, 2026 · Related Folivis guide:supplements without known deficiency
NIH notes that biotin deficiency can affect hair, while evidence for supplementation beyond deficiency is limited; biotin can interfere with some lab tests.
Government health information · Relevant to deficiency and test-interference context.
Open NIH ODSChecked October 20, 2026 · Related Folivis guide:supplements without known deficiency
Beoy et al. (2010), PMID 24575202, studied 38 people taking 100 mg mixed tocotrienols for eight months and reported improved hair counts, not hair weight.
Small ingredient study · NOURISH contains a different 50 mg formula; efficacy cannot be inferred.
Open PubMedChecked October 20, 2026 · Related Folivis guide:supplements without known deficiency
The system combines RESET shampoo, SUPPORT serum and NOURISH supplement. Product descriptions list 300 mL, 60 mL and 120 capsules (30 servings at four daily).
Folivis product fact · Describes roles and quantities; it does not require buying all three.
Review product factsChecked October 20, 2026 · Related Folivis guide:choosing product roles
American Academy of Dermatology Association
Assessment begins with onset, duration, scalp/nail examination and hair characteristics; blood tests or biopsy depend on suspected causes. More than one cause can coexist, such as postpartum shedding with early hereditary thinning.
People with different causes of hair loss; medication examples have condition-specific populations.
Source date: 2022-12-13 · Checked 20 October 2026
Read the original sourceBritish Association of Dermatologists
Diffuse shedding can appear around three months after a trigger, including childbirth, illness, surgery, marked weight loss, extreme dieting or medication changes. History and scalp examination guide diagnosis; blood tests may assess iron deficiency or thyroid conditions.
The guidance covers telogen effluvium across ages and sexes; the related Folivis article is written for adults.
Source date: 2025-10 · Checked 20 October 2026
Read the original sourceNHS
Hair loss may be hereditary or related to illness, stress, weight loss or iron deficiency. Assessment of cause should precede a commercial hair-clinic decision.
People worried about hair loss; UK health-system access details.
Source date: not reliably confirmed · Checked 20 October 2026
Read the original sourceNIDDK, National Institutes of Health
Dry or thinning hair can accompany fatigue, cold intolerance and menstrual changes in hypothyroidism. Symptoms alone cannot diagnose hypothyroidism; medical history, examination and thyroid testing are used.
People being assessed for hypothyroidism; not all people with thinning hair.
Source date: 2021-03 · Checked 20 October 2026
Read the original sourceUS Food and Drug Administration
Biotin in supplements can interfere with certain laboratory tests and produce incorrect results. FDA describes falsely low troponin results in susceptible tests.
People taking biotin and clinicians/laboratories using susceptible assays.
Source date: not reliably confirmed · Checked 20 October 2026
Read the original sourceAmerican Academy of Dermatology Association
Frontal fibrosing alopecia can destroy follicles and cause permanent loss. A receding band at the frontal/side hairline and eyebrow loss can be features.
People with possible frontal fibrosing alopecia; often postmenopausal women, also others.
Source date: 2022-08-03 · Checked 20 October 2026
Read the original sourceNIH Office of Dietary Supplements
Ferritin reflects iron stores but inflammation can elevate it. Clinicians may combine several measurements and dietary/blood-loss history to assess iron status.
People with possible iron inadequacy; interpretation varies by clinical context.
Source date: 2025-09-04 · Checked 20 October 2026
Read the original sourceNHS
Sexual side effects can occur and may sometimes persist after stopping. Mood changes and other serious symptoms need prompt medical attention.
People using finasteride; hair-loss versus prostate-use instructions may differ.
Source date: 2023-08-02 · Checked 20 October 2026
Read the original sourceAmerican Academy of Dermatology Association
Postpartum excessive shedding may appear a few months after delivery as estrogen levels fall. Shedding commonly peaks around four months; most recover usual fullness by the child’s first birthday.
Women after childbirth; not every postpartum loss has this explanation.
Source date: 2025-10-02 · Checked 20 October 2026
Read the original sourceBritish Association of Dermatologists
Lichen planopilaris damages follicles and replaces them with scar tissue. Itching, pain, burning or tenderness with perifollicular redness/scaling can occur.
People with suspected inflammatory/scarring scalp loss.
Source date: 2022-11 · Checked 20 October 2026
Read the original sourceAmerican Academy of Dermatology Association
Dermatologists examine the loss areas and nails, sometimes using dermoscopy, biopsy or selected blood tests. Treatment depends on amount, duration, location and age; some limited recent patches regrow without treatment.
People with suspected/diagnosed alopecia areata; adult and pediatric options are explicitly different.
Source date: 2026-10-07 · Checked 20 October 2026
Read the original sourceBritish Association of Dermatologists
Repeated pulling from tight hairstyles can cause localized loss. Stopping tension early can permit improvement; prolonged pulling can destroy follicles permanently.
All ethnic backgrounds exposed to repeated hair tension; texture, style and duration differ.
Source date: 2019-02 · Checked 20 October 2026
Read the original sourceNHS
Dandruff is not caused by poor hygiene. Similar flaking can accompany seborrheic dermatitis, eczema, contact dermatitis, psoriasis or scalp ringworm.
People with scalp flaking; visual features vary with skin tone.
Source date: not reliably confirmed · Checked 20 October 2026
Read the original sourceNHS
Scalp ringworm can cause a scaly rash and patchy hair loss; colour may be less obvious on darker skin. Scalp involvement warrants medical assessment and usually needs prescription antifungal tablets plus shampoo.
People with possible fungal skin/scalp infection, including adults and children.
Source date: 2023-08-03 · Checked 20 October 2026
Read the original sourceUS HHS Office on Women’s Health
Scalp thinning may occur alongside irregular periods, excess facial/body hair or acne. PCOS is not diagnosed from one symptom or a single test; evaluation includes history/examination and selected tests to rule out alternatives.
People with possible PCOS; not all scalp thinning or acne indicates PCOS.
Source date: 2025-10-24 · Checked 20 October 2026
Read the original sourceDailyMed / US National Library of Medicine; label supplied by L. Perrigo Company
The label describes temporary early shedding for up to two weeks and says to consult a physician if it continues beyond that. Regrowth varies; this label describes possible results at three months and review if absent at six months.
Specific US women’s 5% foam for adults with gradual top-of-scalp thinning; not all minoxidil formulations or prescriptions.
Source date: 2024-04-10 · Checked 20 October 2026
Read the original sourceAmerican Academy of Dermatology Association
Gentle shampooing, conditioning and detangling reduce avoidable damage to fragile strands. Repeated tight styling and excessive heat can damage hair; lowering tension and heat are useful care changes.
People with fragile/thinning hair; care does not substitute for cause-specific treatment.
Source date: not reliably confirmed · Checked 20 October 2026
Read the original sourceAmerican Academy of Dermatology Association
Hair loss can appear as gradual pattern changes or sudden patches/clumps. Eyebrow, eyelash or other body-hair change can matter alongside the scalp.
People noticing scalp or body-hair changes.
Source date: not reliably confirmed · Checked 20 October 2026
Read the original sourceNICHD, National Institutes of Health
Symptoms can affect menstrual cycles, acne, facial/body hair and metabolic health. The current page also calls PCOS Polyendocrine Metabolic Ovary Syndrome (PMOS).
People with possible PCOS; adolescent diagnosis differs from adult assessment.
Source date: not reliably confirmed · Checked 20 October 2026
Read the original sourceNational Institute of Diabetes and Digestive and Kidney Diseases
Blood counts can include hemoglobin and other red-cell measures. Iron-status evaluation may include blood iron, transferrin and ferritin.
People being evaluated for anemia of inflammation or chronic disease; not all people with hair loss.
Source date: 2018-09 · Checked 2026-10-20
Read the original sourceU.S. Food and Drug Administration
The U.S. label identifies baricitinib for adults with severe alopecia areata. The label includes required evaluations, monitoring, warnings and dose information for prescribers.
FDA-labeled baricitinib uses, including adults with severe alopecia areata; trial population and label limitations are specific.
Source date: 2026-06 · Checked 2026-10-20
Read the original sourceNIH Office of Dietary Supplements
Biotin deficiency is rare and may include hair loss among other signs. Evidence for biotin supplements promoting hair health is limited; the hair reports described are case reports in children with specific conditions.
People considering biotin intake; deficiency and test-interference contexts vary.
Source date: 2022-01-10 · Checked 2026-10-20
Read the original sourceDailyMed, US National Library of Medicine; manufacturer-supplied US prescription label
The approved tablet indication on this US label is hypertension inadequately controlled with specified other antihypertensive therapy. Oral minoxidil has systemic vasodilating effects and may produce fluid retention and an increased heart rate.
US oral minoxidil label for severe or difficult-to-control hypertension; not an approved hair-loss indication or a low-dose hair-loss safety cohort.
Source date: not supplied · Checked 2026-10-20
Read the original sourceGloucestershire Hospitals NHS Foundation Trust
The specialist team assesses the patient and agrees treatment before prescribing. The leaflet describes pulse and blood-pressure monitoring during treatment.
Patients assessed by this UK hospital hair specialist team for pattern hair loss; local specialist oral-minoxidil pathway.
Source date: not supplied · Checked 2026-10-20
Read the original sourceJAMA Dermatology; Penha, Miot, Kasprzak and Muller Ramos
The randomized trial compared a specified oral minoxidil regimen with 5% topical minoxidil over 24 weeks. Oral treatment did not demonstrate overall superiority in the trial's main comparisons.
90 men aged 18–55 with androgenetic alopecia enrolled at one Brazilian center; 24-week comparison, with incomplete follow-up.
Source date: 2024-04-10 · Checked 2026-10-20
Read the original sourceBritish Association of Dermatologists and British Hair and Nail Society
Male pattern hair loss involves genetic and hormonal factors, including DHT-associated follicular miniaturization. Finasteride reduces DHT and is a licensed oral treatment option for male pattern loss.
Men with possible androgenetic alopecia; patient-information consensus rather than an original randomized trial.
Source date: 2024-06 · Checked 2026-10-20
Read the original sourceOrganon; FDA-approved labeling hosted by DailyMed, US National Library of Medicine
Indicated for male pattern hair loss; efficacy in bitemporal recession is not established. The label describes three months or more before benefit is generally observed, continued treatment to sustain benefit and reversal within twelve months after withdrawal.
US Propecia labeling for male androgenetic alopecia; excludes use in women and pediatric patients.
Source date: 2022-08 · Checked 2026-10-20
Read the original sourceUK Medicines and Healthcare products Regulatory Agency
Updated advice highlights depression, suicidal thoughts and sexual dysfunction, including persistent sexual symptoms after treatment has stopped. Before prescribing, review psychiatric history and provide the patient card and leaflet; monitor psychiatric and sexual symptoms.
Patients using finasteride, with distinct instructions for 1 mg hair-loss use versus 5 mg prostate use or dutasteride.
Source date: 2026-05-11 · Checked 2026-10-20
Read the original sourceAmerican Academy of Dermatology Association
Selection of a qualified surgeon and examination of donor and recipient areas are central to suitability. Some younger patients may be advised to wait and use medical treatment first.
Adults considering hair transplantation; candidacy requires clinical evaluation and donor/recipient suitability.
Source date: not supplied · Checked 2026-10-20
Read the original sourceInternational Society of Hair Restoration Surgery
Consumers should ask about qualifications, licensure, experience, team roles, financial terms, procedure duration and recovery expectations. Both strip harvesting and FUE leave scars; completely scarless transplant claims are misleading.
Consumers considering a hair-restoration procedure; questions for discussion rather than individualized surgical advice.
Source date: not supplied · Checked 2026-10-20
Read the original sourceInternational Society of Hair Restoration Surgery
Skin incisions for removing tissue or making recipient sites are surgical procedures, including FUE harvesting and robotic operations. The society calls for properly trained and licensed physicians for these surgical roles.
Hair-restoration surgical operators and consumers across jurisdictions; delegation rules depend on local licensure.
Source date: 2024-07-13 · Checked 2026-10-20
Read the original sourceNHS
FUT removes a donor strip and leaves a linear scar; FUE removes units individually and leaves multiple small scars. Surgeon qualifications, experience, complications and follow-up should be discussed before surgery.
People considering cosmetic hair-transplant surgery, with England-specific registration information and UK cost context.
Source date: not supplied · Checked 2026-10-20
Read the original sourceNHS
Finasteride is a prescription medicine and can be used for male pattern loss. Finasteride can affect PSA blood-test results, so the clinician should be informed before testing.
UK readers using or considering finasteride for male pattern loss or prostate enlargement; indications distinguished.
Source date: 2023-08-02 · Checked 2026-10-20
Read the original sourceNHS
Read: NHS causes, normal shedding context, consultation and treatment limitations read.
American Family Physician / American Academy of Family Physicians
Read: Public abstract and SORT recommendation table read; full subscription article was not accessed.
DermNet
Read: DermNet hair-shaft structure and external physical/chemical injury sections read.
Alopecia UK
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
DermNet
Read: DermNet female-pattern introduction, cause, pattern, miniaturisation and management sections read; no individualized prescribing.
NHS
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
NHS
Read: NHS breathing/swelling emergency features read; no local emergency number copied.
International Society of Hair Restoration Surgery
Read: ISHRS educational release read for appearance signs and distinct patterns; no product trial inference.
British Association of Dermatologists
Read: Primary BAD telogen-effluvium leaflet retrieved; trigger history and delayed shedding context checked.
American Academy of Dermatology Association
Read: Primary patient-education page read at diagnosis/examination, supplement and wigs/concealers sections; no clinical trial inferred.
American Academy of Dermatology
Read: AAD post-COVID substantive sections read: delayed diffuse shedding, alopecia-areata distinction and assessment; no prevalence adopted.
Novo Nordisk
Read: June 2026 prescribing information hair-loss table and named hair-loss section read; specified 2.4 mg pooled studies only used.
Eli Lilly
Read: August 2026 prescribing information pooled adverse-reaction table and hair-loss section read.
British Association of Dermatologists
Read: October 2025 BAD leaflet delay and trigger sections read.
American Society for Nutrition
Read: PubMed PMID 40445127 abstract read for multidisciplinary nutrition assessment and gastrointestinal/nutrition priorities; inaccessible ASN landing page not claimed read.
NIH Office of Dietary Supplements
Read: Primary NIH fact sheet iron-status, depletion-before-anemia, diet/absorption and excess-intake sections read.
US Food and Drug Administration
Read: FDA substantive biotin/troponin safety explanation and assay-table purpose read.
DermNet
Read: DermNet hair-shaft structure and external physical/chemical injury sections read.
Cleveland Clinic
Read: Cleveland Clinic overview, childbirth mechanism, timeline, daily-care and follow-up sections read.
National Institute of Diabetes and Digestive and Kidney Diseases
Read: NIDDK symptom, postpartum-thyroiditis context, diagnosis and treatment overview read.
NICHD
Read: NICHD symptoms page read for menstrual, acne, unwanted-hair and metabolic context; no individual diagnosis.
DermNet
Read: DermNet history, oral-contraceptive changes, patterns and time-course sections read; no unsupervised drug stop advised.
Cochrane
Read: Cochrane plain-language summary and abstract read; search through July 2015 and evidence-quality limits retained.
DailyMed / US National Library of Medicine
Read: DailyMed Women’s Rogaine 5% foam Drug Facts, directions, pregnancy/breastfeeding, adverse-event and continued-use sections read.
Journal of the International Society of Sports Nutrition / PubMed
Read: PubMed abstract, methods, participant count, outcomes, conflict statement and figure descriptions read; PMC direct request challenged; no full-text statistical reanalysis.
International Journal of Trichology / PubMed Central
Read: PMC search-rendered abstract and methods read: collected hair samples, exposure and tensile-strength/elasticity results; not a clinical regrowth study.
Journal of the Pakistan Medical Association / PubMed
Read: PubMed search-rendered primary abstract: hair samples, three-month hard-water/deionized exposure and tensile-strength result; direct page returned an empty shell.
American Academy of Dermatology Association
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
American Academy of Dermatology Association
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
Eplasty / PubMed
Read: Search-rendered PubMed abstract and figure descriptions read; nine participants, standardized device, duration, thickness and no density advantage over control noted; full paper not read.
Skinmed / PubMed
Read: Search-rendered PubMed abstract read: randomized 100 participants, rosemary versus2% minoxidil, six months and hair-count result; no full paper read.
US Food and Drug Administration
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
MedlinePlus Genetics / US National Library of Medicine
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
American Academy of Dermatology Association
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
MedlinePlus Genetics / US National Library of Medicine
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
American Academy of Dermatology Association
Read: Current AAD patient article read: early presentation, topical minoxidil and finasteride roles, response variability and continuing-use considerations.
UK Medicines and Healthcare products Regulatory Agency
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
American Academy of Dermatology Association
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
American Academy of Dermatology Association
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
American Academy of Dermatology Association
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
MedlinePlus Genetics / US National Library of Medicine
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
NHS
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
Mayo Clinic
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
American Academy of Dermatology Association
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
Cleveland Clinic
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
Skin of Color Society
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
Applied Microscopy / PubMed Central
Read: Full open-access article abstract, methods, microscopy results and discussion read; laboratory repeated-bleach samples, no clinical product trial.
DailyMed / US National Library of Medicine
Read: Current specific US men5% solution Drug Facts and consumer instructions read, including drying, continued use, discontinuation and missed use; not generalized to other routes/populations.
DailyMed / US National Library of Medicine
Read: Current specific US women5% foam Drug Facts and consumer leaflet read; early shedding/review, continued use, discontinuation, warnings and missed-use instructions remain population-specific.
DailyMed / US National Library of Medicine
Read: Current specific US men5% solution Drug Facts and consumer leaflet read: early shedding, stop-use symptoms and actual-use instructions.
Organon / DailyMed
Read: FDA-approved prescribing and patient information read: male-pattern indication, bitemporal limit, use/withdrawal timing, DHT mechanism, reproductive handling, PSA and adverse-event sections.
Giornale Italiano di Dermatologia e Venereologia / PubMed
Read: PubMed primary trial abstract read: randomized double-blind shampoo study, women with AGA,six months and hair-pull primary endpoint.
Skin Pharmacology and Physiology / PubMed
Read: Search-rendered PubMed abstract and PMC results excerpt read: randomized open-label noninferiority design,210 men,0.2% caffeine liquid versus5% minoxidil,six-month anagen-ratio endpoint and margin context; not full paper.
Healthcare / PubMed
Read: PubMed systematic-review abstract read: search,9 trials,684 participants,GRADE ratings and design/reporting limitations; no full-text meta-analysis rerun.
Archives of Pharmacal Research / PubMed
Read: Search-rendered PubMed abstract read: AHK-Cu identity,isolated human follicles and cultured dermal papilla cells; ex vivo/in vitro rather than a retail product clinical trial.
International Journal of Cosmetic Science / PubMed
Read: Search-rendered PubMed abstract and affiliation metadata read: women with self-perceived thinning,eight-week randomized double-blind shampoo/leave-on versus corresponding placebos,phototrichogram/TEWL/scalp-marker findings.
MedlinePlus / American Society of Health-System Pharmacists
Read: Current official patient guidance read: relevant causes, use/handling or safety sections for the attached article; no independent review of Folivis outcomes.
International Journal of Cosmetic Science / University of Liège repository
Read: University-hosted original8-page paper read: synopsis,methods,results and discussion;150 men,three1% shampoos,six months,separate shedding/diameter/density outcomes,no bland control and seasonality context.
Memorial Sloan Kettering Cancer Center, About Herbs
Read: MSKCC professional clinical-summary and patient laboratory-interference sections read; NIH biotin direct access returned403.
MedlinePlus / US National Library of Medicine
Read: MedlinePlus complete substantive ferritin measurement, use, low/high interpretation and inflammation text read.
NIH Office of Dietary Supplements
Read: NIH vitamin-D assessing-status, units and assay-variability text read; no individualized treatment thresholds used.
NIH Office of Dietary Supplements
Read: NIH excess-zinc, copper effects and adult40mg upper-limit text read.
NIH Office of Dietary Supplements
Read: NIH adult upper-limit table and2023 EFSA255mcg explanation read; U.S.reference400mcg retained as distinct jurisdiction.
National Center for Complementary and Integrative Health
Read: NIH current hair-loss limited-evidence, safety and medicine disclosure sections read.
journals.sagepub.com
Read: Publisher abstract read: open-label100men,24months,320mgSerenoaversus1mgfinasteride,global-photo scores and38%/68%improved; full paper not newly read.
National Center for Complementary and Integrative Health
Read: NIH substantive efficacy and safety text read: thyroid/autoimmune/surgery,pregnancy/breastfeeding,medicine categories,liver reports and limited long-term data.
pubmed.ncbi.nlm.nih.gov
Read: PubMed abstract read: 38 assigned, 100 mg mixed tocotrienols, 8 months, defined-area count and hair-clipping weight; direct PMC full text challenged, no new full-text review claimed.
National Center for Complementary and Integrative Health
Read: NIH explanation of control groups and blinded controlled studies read.
NIH Office of Dietary Supplements
Read: NIH vegetarians/vegans paragraph read: naturally occurring animal-food sources and fortified-food/supplement provision.
National Center for Complementary and Integrative Health
Read: NIH minimizing-bias methods paragraphs read.
www.folivis.com
Read: Current published guarantee substantive eligibility,timing,photographs,refund and reaction instructions read.
National Center for Complementary and Integrative Health
Read: NIH results, replication, clinical/statistical significance and financial-relationship explanation read.
National Center for Complementary and Integrative Health
Read: NIH sample-size explanation read.
Folivis
Read: Current Shopify Admin snapshot read:once daily,clean dry/towel-dried scalp,leave-in,storage and stop-use directions.
Penn Medicine
Read: Penn Medicine substantive types,scalp symptoms and diagnostic context read.
British Skin Foundation
Read: British Skin Foundation complete substantive traction explanation,history/symptoms and self-care section read.
Folivis
Read: Current Shopify Admin product facts snapshot read in geo-evidence-foundation-20261020/reports/shopify-product-facts-current.json: complete serving, composition, directions and warnings.
DailyMed / Cardinal Health
Product directions, timing, irritated-scalp and other-scalp-medicine warnings read.
Scope: Specific product and population; not an oral-minoxidil or universal treatment timetable.
Read the sourceChecked 2026-10-20
DailyMed / Organon
Indication, dosing and periodic reassessment text read.
Scope: Prescription medicine for male pattern hair loss; individual management belongs with the prescriber.
Read the sourceChecked 2026-10-20
MedlinePlus Genetics / US National Library of Medicine
Description of androgen-related signs read.
Scope: The combination of signs informs assessment; scalp thinning alone does not diagnose PCOS.
Read the sourceChecked 2026-10-20
LactMed / US National Library of Medicine
Official PubMed LactMed excerpt read; full Bookshelf chapter was not accessible.
Scope: Supports a prescriber discussion and exposure review, not a universal restart date or individual clearance.
Read the sourceChecked 2026-10-20
American Academy of Dermatology Association
Symptoms and nail-change sections read.
Scope: Nail signs must be assessed with the wider clinical history; they are not a stand-alone diagnosis.
Read the sourceChecked 2026-10-20
Koyama et al. / PubMed
Abstract and figure captions read; full PMC paper was blocked and not claimed read.
Scope: Small healthy-volunteer study; does not establish a device treatment for clinical hair loss.
Read the sourceChecked 2026-10-20
US Food and Drug Administration
Drug Facts fields and their purposes read.
Scope: Label information and a research paper serve different reading tasks.
Read the sourceChecked 2026-10-20
National Center for Complementary and Integrative Health
Abstract and main-section explanation read.
Scope: Research-literacy guidance, not evidence of any Folivis outcome.
Read the sourceChecked 2026-10-20
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Replication and Peer Review sections read.
Scope: Foundational education-focused research-literacy text; used only for general process definitions, not hair-treatment evidence.
Read the sourceChecked 2026-10-20
Cleveland Clinic
Hormonal mechanism, timeline and follow-up sections read.
Scope: General postpartum education; individual persistence or recurrence needs assessment.
Read the sourceChecked 2026-10-20
British Association of Dermatologists
Hair-cycle, recurrence, assessment and coexisting pattern-loss sections read.
Scope: General clinical guidance; timing alone does not diagnose a person’s cause.
Read the sourceChecked 2026-10-20
Chaikittisilpa et al. / Menopause / PubMed
PubMed abstract, recruitment, assessed population and cross-sectional design read.
Scope: Thai clinical setting; not a population-wide forecast or a Folivis product trial.
Read the sourceChecked 2026-10-20
NHS
Symptom variation and period-history sections read.
Scope: Supports history-taking prompts, not a diagnostic score or attribution of hair loss to HRT.
Read the sourceChecked 2026-10-20
Joint advisory: ACLM, ASN, OMA and The Obesity Society
PubMed-indexed abstract including objectives and methods read; no full-paper review claimed.
Scope: Not a clinical trial of Folivis NOURISH or proof that a named supplement prevents associated shedding.
Read the sourceChecked 2026-10-20
American Hair Loss Association
Shedding versus breakage definitions and Serum Iron and Ferritin section read.
Scope: Association patient education, not a trial establishing a hair-growth target.
Read the sourceChecked 2026-10-20
DermNet
Hair-cycle, telogen club-hair and pattern-loss sections read.
Scope: A strand’s end alone does not diagnose why shedding changed.
Read the sourceChecked 2026-10-20
D. H. Rushton / Clinical and Experimental Dermatology / PubMed
PubMed-indexed abstract read through the search result; direct page returned no article text.
Scope: 2002 clinical review; this observation is not a validated home diagnostic test or evidence for a universal iron target.
Read the sourceChecked 2026-10-20
Kunz, Seifert and Trüeb / Dermatology / PubMed
PubMed abstract methods, exclusions and results read.
Scope: Group-level retrospective evidence; does not diagnose an individual episode as seasonal.
Read the sourceChecked 2026-10-20
National Heart, Lung, and Blood Institute
Blood-loss causes, diagnosis and treatment sections read.
Scope: Does not establish the cause of an individual’s hair loss or replace assessment of the bleeding.
Read the sourceChecked 2026-10-20
DailyMed / Women’s Rogaine
Product strength, directions and stop-use warnings read.
Scope: US product-specific label; follow the current pack and professional advice.
Read the sourceChecked 2026-10-20
DailyMed / Women’s Rogaine
Product strength, directions and stop-use warnings read.
Scope: A solution schedule cannot be inferred from a foam label; country and product instructions differ.
Read the sourceChecked 2026-10-20
Gloucestershire Hospitals NHS Foundation Trust
What is pattern hair loss? section read in this review, in addition to the previously recorded prescribing pathway.
Scope: A typical sequence helps assessment; one photograph cannot establish a diagnosis.
Read the sourceChecked 2026-10-20